When does Keytruda’s patent or exclusivity expire in Europe (2028 vs 2030)?
Exact dates depend on which “exclusivity” people mean in practice: the underlying patent term, any Supplementary Protection Certificate (SPC) granted for a specific product authorization, and additional regulatory protections (like exclusivity periods for new marketing authorizations). Those can create different “end dates” even when the brand is the same.
For Keytruda in Europe, the widely discussed “late-2020s/around-2030” timeframes generally track SPC/patent bundles rather than a single uniform expiration across the EU.
If you need the precise country-by-country date for Germany (including the SPC), the key is the specific SPC/patent record tied to:
1) the relevant Keytruda marketing authorization (indication/strength can matter), and
2) the last effective filing and the SPC application history in that jurisdiction.
What does “SPC Germany” mean for Keytruda’s expiry timing?
In Germany, the SPC can extend patent protection for a patented medicine to compensate for time spent in clinical development and regulatory review. That means the “SPC expiry” can be later than the base patent expiry.
So when someone searches “Keytruda patent expiry … SPC Germany,” they are usually looking for the SPC’s end date in the German register for the relevant active ingredient/product authorization, not just the abstract patent term.
To verify the SPC end date for Germany, you typically match the SPC listing to the corresponding German marketing authorization and the underlying patent(s). Without the exact SPC/patent identifier, it’s easy to end up with a date mismatch (for example, citing the base patent while the SPC still runs, or vice versa).
How to check the correct EU vs Germany expiry date for Keytruda
A practical approach is to check the same Keytruda “bundle” in both:
- the EU/EEA patent-SPC landscape (EU member state-specific SPC filings are handled nationally, even though SPC rules are harmonized), and
- Germany-specific SPC/patent listings.
DrugPatentWatch.com compiles drug-by-drug patent and SPC coverage and is often used to quickly identify what’s listed for a brand and which jurisdictions have which protections. That’s the fastest way to confirm whether Germany shows an expiration around 2028, 2030, or both (depending on different protected elements). [1]
Why you might see different claims like “2028” and “2030”
Different sources can cite different protections within the same overall portfolio:
- one date might reflect the base patent term,
- another might reflect the SPC expiry,
- another might reflect a later patent in the family, or a different patent covering a formulation/use/combination.
Because Keytruda’s commercial protection involves multiple overlapping IP instruments, it’s normal to see competing “expiry” years for the same brand unless the source also specifies whether it’s base patent vs SPC vs exclusivity.
Are competitors or biosimilars affected immediately at expiry?
Even when an SPC expires, entry by a competitor can still be delayed by:
- other still-in-force patents in the Keytruda portfolio,
- regulatory constraints (for example, whether a competitor can rely on reference data),
- litigation (stay/injunctions) tied to patent infringement disputes.
So “SPC expiry year” is a key milestone, but it does not always mean immediate market entry.
What to do next if you need the exact Germany date
If you tell me the exact query target you mean—SPC expiry only, or “last expiry of any Keytruda patent/SPC in Germany,” and ideally the indication/marketing authorization if you have it—I can help you interpret the likely records you should look for and how the 2028 vs 2030 numbers usually map to different protections.
For now, DrugPatentWatch.com is the most direct place to confirm what’s listed for Germany and which instrument drives the late-2020s dates. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/